<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02216149</url>
  </required_header>
  <id_info>
    <org_study_id>HUS-01/2013</org_study_id>
    <secondary_id>2013-003976-11</secondary_id>
    <nct_id>NCT02216149</nct_id>
  </id_info>
  <brief_title>Effects of S-1 and Capecitabine on Coronary Artery Blood Flow</brief_title>
  <acronym>FluoHeart</acronym>
  <official_title>Effects of S-1 and Capecitabine in Combination With Oxaliplatin on the Coronary Artery Blood Flow in Patients Metastatic Gastrointestinal Tract Adenocarcinoma: a Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heikki Joensuu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are
      occasionally associated with cardiac toxicity. Clinical fluoropyrimidine cardiotoxicity is
      infrequent, but subclinical toxicity may be much more common. Cardiac toxicity may be less
      frequent with S-1 as compared with 5-fluorouracil and capecitabine, but head-to-head
      comparisons are lacking. The purpose of the study is to compare 2 measures of subclinical
      coronary artery microvascular dysfunction, the coronary flow reserve and the coronary flow
      response to a cold pressor test, in a patient population who are being treated for
      adenocarcinoma of the gastrointestinal tract with one of 2 oxaliplatin-containing regimens,
      either with oxaliplatin plus S-1 or with oxaliplatin plus capecitabine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of coronary artery dysfunction</measure>
    <time_frame>3 months</time_frame>
    <description>The frequency of subclinical coronary artery dysfunction is as assessed by comparing the coronary flow reserve during chemotherapy with the baseline coronary flow reserve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary artery blood flow rate</measure>
    <time_frame>3 months</time_frame>
    <description>The coronary artery blood flow rate is measured with ultrasound. The rates are compared with the baseline and between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac arrythmias during 24-hour electrocardiogram registration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events between the allocation groups</measure>
    <time_frame>3 months</time_frame>
    <description>by CTCAE.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to chemotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>by RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophagus Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Small Bowel Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>S-1 plus oxaliplatin (SOX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxaliplatin plus capecitabine (XELOX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 25 mg/m2/day BID d1-14</description>
    <arm_group_label>S-1 plus oxaliplatin (SOX)</arm_group_label>
    <arm_group_label>Oxaliplatin plus capecitabine (XELOX)</arm_group_label>
    <other_name>Teysuno</other_name>
    <other_name>tegafur/gimeracil/oteracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14</description>
    <arm_group_label>S-1 plus oxaliplatin (SOX)</arm_group_label>
    <arm_group_label>Oxaliplatin plus capecitabine (XELOX)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has given written informed consent.

          -  Is at least 18 years of age.

          -  Has advanced or metastatic gastrointestinal tract adenocarcinoma.

          -  No previous cancer chemotherapy for cancer.

          -  Measurable or evaluable lesions according to RECIST v1.1 criteria.

          -  Is able to take medications orally.

          -  Has ECOG performance status 0 or 1.

          -  Has a life expectancy of at least 3 months.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Cancer considered operable without prior chemotherapy.

          -  Prior chemotherapy to cancer.

          -  Previous therapy with fluoropyrimidines or anthracyclines for any indication.

          -  Inability to swallow tablets.

          -  Known brain metastasis or leptomeningeal metastasis.

          -  History of myocardial infarction, coronary stenting/graft.

          -  History of unstable angina, coronary/peripheral artery bypass graft.

          -  History of cerebrovascular accident or transient ischemic attack.

          -  History of pulmonary embolism or deep vein thrombosis.

          -  Symptomatic congestive heart failure.

          -  Ongoing cardiac dysrhythmias.

          -  Patients with any cardiac disease that requires regular medication.

          -  Hypertensive crisis or severe hypertension that is not controlled.

          -  Is a pregnant or lactating female.

          -  The cardiac arterial flow tests cannot be done.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki Joensuu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heikki Joensuu, MD</last_name>
    <phone>947173200</phone>
    <phone_ext>+358</phone_ext>
    <email>heikki.joensuu@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pia Österlund, MD</last_name>
    <phone>947173297</phone>
    <phone_ext>+358</phone_ext>
    <email>pia.osterlund@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Joensuu, MD</last_name>
      <phone>947173200</phone>
      <phone_ext>+358</phone_ext>
      <email>heikki.joensuu@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Pia Österlund, MD</last_name>
      <phone>947173297</phone>
      <email>pia.osterlund@hus.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Heikki Joensuu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pia Österlund, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Heikki Joensuu</investigator_full_name>
    <investigator_title>MD, professor</investigator_title>
  </responsible_party>
  <keyword>fluoropyrimidine</keyword>
  <keyword>S-1</keyword>
  <keyword>Teysuno</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>coronary artery flow</keyword>
  <keyword>coronary artery dysfunction</keyword>
  <keyword>gastrointestinal tract cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

